Gossamer Bio Past Earnings Performance
Past criteria checks 0/6
Gossamer Bio has been growing earnings at an average annual rate of 7.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 103.9% per year.
Key information
7.7%
Earnings growth rate
24.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 103.9% |
| Return on equity | -132.3% |
| Net Margin | -68.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Sep 10Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts
Aug 14
Peaking Back In On Gossamer Bio
Sep 27Gossamer Bio to raise $120M in a private equity placement
Jul 13Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
Jun 25Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Jan 19Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?
Sep 22Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares
Jan 28Gossamer Bio (GOSS) Investor Presentation - Slideshow
Nov 18Revenue & Expenses Breakdown
How Gossamer Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 105 | -72 | 36 | 132 |
| 30 Jun 24 | 96 | -81 | 37 | 129 |
| 31 Mar 24 | 0 | -173 | 38 | 130 |
| 31 Dec 23 | 0 | -180 | 38 | 135 |
| 30 Sep 23 | 0 | -187 | 42 | 147 |
| 30 Jun 23 | 0 | -207 | 44 | 160 |
| 31 Mar 23 | 0 | -221 | 46 | 166 |
| 31 Dec 22 | 0 | -229 | 48 | 171 |
| 30 Sep 22 | 0 | -230 | 43 | 170 |
| 30 Jun 22 | 0 | -231 | 44 | 169 |
| 31 Mar 22 | 0 | -234 | 44 | 171 |
| 31 Dec 21 | 0 | -234 | 46 | 170 |
| 30 Sep 21 | 0 | -242 | 51 | 168 |
| 30 Jun 21 | 0 | -240 | 50 | 167 |
| 31 Mar 21 | 0 | -247 | 50 | 161 |
| 31 Dec 20 | 0 | -243 | 50 | 161 |
| 30 Sep 20 | 0 | -233 | 45 | 165 |
| 30 Jun 20 | 0 | -224 | 44 | 163 |
| 31 Mar 20 | 0 | -202 | 42 | 160 |
| 31 Dec 19 | 0 | -180 | 39 | 143 |
| 30 Sep 19 | 0 | -164 | 41 | 127 |
| 30 Jun 19 | 0 | -165 | 55 | 105 |
| 31 Mar 19 | 0 | -154 | 49 | 78 |
| 31 Dec 18 | 0 | -147 | 44 | 55 |
| 30 Sep 18 | 0 | -115 | 30 | 30 |
| 30 Jun 18 | 0 | -66 | 7 | 11 |
| 31 Mar 18 | 0 | -33 | 3 | 4 |
| 31 Dec 17 | 0 | -7 | 0 | 1 |
Quality Earnings: GOSS is currently unprofitable.
Growing Profit Margin: GOSS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GOSS is unprofitable, but has reduced losses over the past 5 years at a rate of 7.7% per year.
Accelerating Growth: Unable to compare GOSS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GOSS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GOSS has a negative Return on Equity (-132.35%), as it is currently unprofitable.